|
|
|
Volumn 24, Issue 5 SUPPL. 17, 1997, Pages
|
|
Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIHISTAMINIC AGENT;
CLEMASTINE;
DOXORUBICIN;
EPIRUBICIN;
GRANULOCYTE COLONY STIMULATING FACTOR;
HISTAMINE H2 RECEPTOR ANTAGONIST;
PACLITAXEL;
RANITIDINE;
STEROID;
ANTINEOPLASTIC AGENT;
ADULT;
ALOPECIA;
ARTHRALGIA;
BREAST CANCER;
CANCER COMBINATION CHEMOTHERAPY;
CARDIOTOXICITY;
CLINICAL PROTOCOL;
CLINICAL TRIAL;
CONFERENCE PAPER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOSE RESPONSE;
DRUG MECHANISM;
FEMALE;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
MAJOR CLINICAL STUDY;
MYALGIA;
NAUSEA;
NEUTROPENIA;
ORAL DRUG ADMINISTRATION;
PERIPHERAL NEUROPATHY;
PHASE 2 CLINICAL TRIAL;
PREMEDICATION;
PRIORITY JOURNAL;
REMISSION;
VOMITING;
AGED;
ARTICLE;
BREAST TUMOR;
FEASIBILITY STUDY;
METASTASIS;
MIDDLE AGED;
ADULT;
AGED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
EPIRUBICIN;
FEASIBILITY STUDIES;
HUMANS;
MIDDLE AGED;
NEOPLASM METASTASIS;
PACLITAXEL;
|
|
EID: 0030725305
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (28)
|
|
References (16)
|
